Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $62.25 Consensus Target Price from Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been assigned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $62.25.

A number of equities analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, January 2nd. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, December 19th. Finally, Citigroup began coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 target price for the company.

Celldex Therapeutics Stock Performance

CLDX stock opened at $24.02 on Wednesday. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -9.35 and a beta of 1.62. The business’s 50 day moving average price is $25.64 and its two-hundred day moving average price is $31.45. Celldex Therapeutics has a fifty-two week low of $22.17 and a fifty-two week high of $53.18.

Insider Activity

In other news, CEO Anthony S. Marucci acquired 11,500 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. The trade was a 39.95 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Celldex Therapeutics in the 2nd quarter worth approximately $76,000. KBC Group NV increased its holdings in Celldex Therapeutics by 31.2% during the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 495 shares during the last quarter. AQR Capital Management LLC raised its position in Celldex Therapeutics by 23.7% in the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 1,504 shares during the period. Handelsbanken Fonder AB boosted its stake in shares of Celldex Therapeutics by 23.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock worth $469,000 after acquiring an additional 2,600 shares during the last quarter. Finally, Point72 DIFC Ltd grew its position in shares of Celldex Therapeutics by 101.7% during the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 7,116 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.